Medical
-
TFF Pharmaceuticals said that in vitro testing has confirmed the efficacy of a monoclonal antibody against Ebolavirus Zaire and a recombinant vesicular stomatitis virus (rVSV) vaccine candidate against Venezuelan equine encephalitis virus formulated using the… Read more . . .
-
Insmed Incorporated has announced data from a Phase 1 study of its treprostinil palmitil inhalation powder (TPIP) in healthy volunteers demonstrated that TPIP was generally safe and well tolerated and had a lower Cmax and longer… Read more . . .
-
The Central European Biotech Incubator and Accelerator (CEBINA) has announced a partnership with Ursapharm Arzneimittel to repurpose Ursapharm’s Pollival azelastine nasal spray for the treatment of COVID-19. In July 2020, CEBINA announced that it had filed a… Read more . . .
-
According to Altimmune, the FDA has now cleared the company’s IND for a Phase 1 trial of its AdCOVID intranasal vaccine candidate, and enrollment in the trial is expected to begin within a week. Altimmune… Read more . . .
-
A Phase 2 study of inhaled budesonide for the treatment of COVID-19 found that patients who received 800 mcg twice daily plus standard of care within 7 days after first experiencing symptoms had a 90%… Read more . . .
-
NeuroRx announced that it has initiated a Phase 2/3 clinical trial of nebulized Zyesami aviptadil (RLF-100) for the treatment of severe COVID-19. In August 2020, NeuroRx announced that the FDA had cleared an IND for… Read more . . .
-
Verona Pharma reported that a Phase 2 study of 3 dose levels of its MDI formulation of ensifentrine in patients with moderate to severe COPD met all of its primary and secondary endpoints, demonstrating significant… Read more . . .
-
Noveome Biotherapeutics has signed a research and development agreement with Walter Reed Army Institute of Research (WRAIR) regarding preclinical studies of an intranasal formulation of Noveome’s ST266 secretome, the company said. Under the agreement, WRAIR… Read more . . .
-
Ovoca Bio announced that it has initiated a Phase 2 study of its BP-101 intranasal synthetic peptide for the treatment of hypoactive sexual desire disorder (HSDD). The dose ranging study, which will take place in… Read more . . .
-
AIM ImmunoTech announced that the Centre for Human Drug Research (CHDR) will conduct a Phase 1 study of an intranasal formulation of the company’s Ampligen rintatolimod, which the company wants to develop for the treatment… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here


